Divis Laboratories' Q1 FY 2026-27 Quarterly Results

Result Summary

• Divis Laboratories Ltd reported a 5.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 24.3%.
• Its expenses for the quarter were down by 2.9% QoQ and up 9.4% YoY.
• The net profit increased 20.1% QoQ and increased 65.5% YoY.
• The earnings per share (EPS) of Divis Laboratories Ltd stood at 33.95 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Divis Laboratories Ltd is a prominent pharmaceutical company known for its manufacturing of active pharmaceutical ingredients (APIs) and intermediates. The company operates in the healthcare and pharmaceutical industry, a sector characterized by rigorous regulations and significant research and development activities. Divis Laboratories has established a strong presence in both domestic and international markets, supplying key pharmaceutical ingredients to various well-known global pharmaceutical companies. The company is recognized for its focus on quality and compliance, which has helped it maintain robust relationships with its clients. As of the data available till October 2023, there are no recent major developments or strategic shifts publicly noted for Divis Laboratories Ltd.

Revenue

In Q1FY27, Divis Laboratories Ltd reported a total income of ₹3,144.00 crores. This represents a quarter-over-quarter (QoQ) increase of 5.3% from ₹2,986.00 crores in Q4FY26, and a year-over-year (YoY) increase of 24.3% from ₹2,529.00 crores in Q1FY26. The growth in revenue is indicative of the company's expanding operations or possibly an increased demand for its products. Over the past year, the company has demonstrated a strong trajectory in income generation, highlighting its effective strategies in capturing market opportunities within the pharmaceutical industry.

Profitability

For Q1FY27, the profit before tax (PBT) for Divis Laboratories Ltd was ₹1,180.00 crores, showing a substantial QoQ increase of 22.5% from ₹963.00 crores in Q4FY26 and a notable YoY increase of 61.0% from ₹733.00 crores in Q1FY26. After accounting for taxes, the profit after tax (PAT) stood at ₹902.00 crores, which is a 20.1% increase QoQ from ₹751.00 crores and a 65.5% increase YoY from ₹545.00 crores. The tax expense for the quarter was ₹278.00 crores, reflecting a 31.1% QoQ increase and a 47.9% YoY increase. Earnings per share (EPS) for Q1FY27 was noted at ₹33.95, showing a significant YoY increase of 65.7% from ₹20.49 in Q1FY26. The company's profitability metrics indicate a solid financial performance over the quarters.

Operating Metrics

The total expenses for Divis Laboratories Ltd in Q1FY27 were reported at ₹1,964.00 crores, which is a decrease of 2.9% QoQ from ₹2,023.00 crores in Q4FY26, but an increase of 9.4% YoY from ₹1,796.00 crores in Q1FY26. This reduction in QoQ expenses, coupled with an increase in revenue, underscores a positive operating performance for the quarter. The company’s ability to manage its expenses effectively while increasing its revenue reflects its operational efficiency. The reported earnings per share of ₹33.95 further affirms the company's profitability and efficient cost management strategies during this period.